Chloroquine inhibits MGC803 gastric cancer cell migration via the Toll-like receptor 9/nuclear factor kappa B signaling pathway

Zhang,Yanli; Li,Yunhong; Li,Yalan; Li,Rui; Ma,Yajun; Wang,Hao; Wang,Yin

doi:10.3892/mmr.2014.2839

Chloroquine inhibits MGC803 gastric cancer cell migration via the Toll-like receptor 9/nuclear factor kappa B signaling pathway

Authors:
- Yanli Zhang
- Yunhong Li
- Yalan Li
- Rui Li
- Yajun Ma
- Hao Wang
- Yin Wang
View Affiliations

Affiliations: Department of Microbiology, College of Basic Medicine, Ningixia Medical University, Yinchuan, Ningxia 750004, P.R. China, Ningxia Key Laboratory of Cerebrocranial Diseases, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China
Published online on: November 3, 2014 https://doi.org/10.3892/mmr.2014.2839
Pages: 1366-1371

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Stimulation of Toll‑like receptor 9 (TLR9) has been associated with invasion in various types of cancer cell in vitro. The present study aimed to evaluate the expression of TLR9 in MGC803 gastric cancer cells and investigate the effect of a non‑specific TLR9 inhibitor, chloroquine (CQ), on MGC803 cell migration via the TLR9/nuclear factor kappa B (NFκB) signaling pathway. The expression of TLR9 was investigated using reverse transcription polymerase chain reaction (RT‑PCR), flow cytometry and western blot analysis. The effects of CQ on MGC803 cell proliferation were measured by MTT colorimetric assay. The mRNA expression levels of cyclooxygenase‑2 (COX‑2), matrix metalloproteinase (MMP)‑2, MMP‑7 and NFκB p65 were evaluated by RT‑PCR in MGC803 cells stimulated by various concentrations of CQ. The migration of gastric cancer cells treated with CQ at 12, 24 and 36 h was measured by wound healing assay. The results indicated that MGC803 cells expressed TLR9 and that CQ had anti‑proliferative effects on MGC803 cells and inhibited mRNA expression of COX‑2, MMP‑2, MMP‑7 and NFκB p65 (P<0.05). Furthermore, CQ inhibited the bioactivity of NFκB p65 and prevented the migration of MGC803 cells in a dose‑dependent manner (P<0.05). In conclusion, the results indicated that the TLR9/NFκB signaling pathway was involved in gastric cancer cell migration and that CQ had anti‑tumor activity.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
2	Taghizadeh-Kermani A, Yahouiyan SZ, AliAkbarian M and Seilanian Toussi M: Prognostic significance of metastatic lymph node ratio in patients with gastric cancer: an evaluation in North-East of Iran. Iran J Cancer Prev. 7:73–79. 2014.PubMed/NCBI
3	D’Angelo G, Di Rienzo T and Ojetti V: Microarray analysis in gastric cancer: A review. World J Gastroenterol. 20:11972–11976. 2014. View Article : Google Scholar
4	Aderem A and Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature. 406:782–787. 2000. View Article : Google Scholar : PubMed/NCBI
5	Takeda K and Akira S: Toll-like receptors in innate immunity. Int Immunol. 17:1–14. 2005. View Article : Google Scholar
6	Oldenburg M, Krüger A, Ferstl R, Kaufmann A, Nees G, Sigmund A, et al: TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification. Science. 337:1111–1115. 2012. View Article : Google Scholar : PubMed/NCBI
7	Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW and Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 4:437–447. 2006. View Article : Google Scholar : PubMed/NCBI
8	Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler wW, et al: Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. 101:1059–1066. 2010. View Article : Google Scholar : PubMed/NCBI
9	Schmausser B, Andrulis M, Endrich S, Lee SK, Josenhans C, Müller-Hermelink HK, et al: Expression and subcellular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol. 136:521–526. 2004. View Article : Google Scholar : PubMed/NCBI
10	Schmausser B, Andrulis M, Endrich S, Müller-Hermelink HK and Eck M: Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol. 295:179–185. 2005. View Article : Google Scholar : PubMed/NCBI
11	Wang X, Xue L, Yang Y, Xu L and Zhang G: TLR9 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. PLoS One. 8:e657312013. View Article : Google Scholar : PubMed/NCBI
12	Wagner H: The immunobiology of the TLR9 subfamily. Trends Immunol. 25:381–386. 2004. View Article : Google Scholar : PubMed/NCBI
13	Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, et al: Identification of the IGF1/PI3K/NFkB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer. 13:5492013. View Article : Google Scholar
14	Zhan Z, Xie X, Cao H, Zhou X, Zhang XD, Fan H, et al: Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination. Autophagy. 10:257–268. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ma YJ, Cui L, Zhang YL and Li XP: Correlations of TLR9 to clinicopathologic features of gastric cancer. J Ningxia Med Univ. 34:126–128. 2012.
16	Romero-Calvo I, Ocón B, Martínez-Moya P, Suárez MD, Zarzuelo A, Martínez-Augustin O and de Medina FS: Reversible Ponceau staining as a loading control alternative to actin in Western blots. Anal Biochem. 401:318–320. 2010. View Article : Google Scholar : PubMed/NCBI
17	Li MZ, Deng L, Wang JJ, Xiao LB, Wu WH, Yang SB and Li WF: Surgical outcomes and prognostic factors of T4 gastric cancer patients without distant metastasis. PLoS One. 9:e1070612014. View Article : Google Scholar : PubMed/NCBI
18	Wang JQ, Jeelall YS, Ferguson LL and Horikawa K: Toll-like receptors and cancer: MYD88 mutation and inflammation. Front Immunol. 5:367–377. 2014. View Article : Google Scholar : PubMed/NCBI
19	Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW and Selander KS: Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate. 67:774–781. 2007. View Article : Google Scholar : PubMed/NCBI
20	Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y, Zhou Y, Zhou H and Wen Z: Tlr9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res. 15:623–630. 2009. View Article : Google Scholar : PubMed/NCBI
21	Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 20:709–760. 2002. View Article : Google Scholar : PubMed/NCBI
22	Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, et al: TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 5:190–198. 2004. View Article : Google Scholar : PubMed/NCBI
23	Maeda S: NF-κB, JNK, and TLR signaling pathways in hepatocarcinogenesis. Gastroenterol Res Pract. 367694:2010.
24	Kakiuchi Y, Tsuji S, Tsujii M, Murata H, Kawai N, Yasumaru M, et al: Cyclooxygenase-2 activity altered the cell-surface ca- rbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res. 62:1567–1572. 2002.PubMed/NCBI
25	Chen R, Alvero AB, Silasi DA, Steffensen KD and Mor G: Cancers take their Toll - the function and regulation of Toll-like receptors in cancer cells. Oncogene. 27:225–233. 2008. View Article : Google Scholar : PubMed/NCBI
26	Jezierska A and Motyl T: Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit. 15:RA32–RA40. 2009.PubMed/NCBI
27	Sims JD, McCready J and Jay DG: Extracellular heat shock protein (Hsp)70 and Hsp90α assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One. 6:e188482011. View Article : Google Scholar
28	Okayama H, Kumamoto K, Saitou K, Hayase S, Kofunato Y, Sato Y, et al: CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep. 22:745–755. 2009.PubMed/NCBI
29	Yeh YC, Sheu BS, Cheng HC, Wang YL, Yang HB and Wu JJ: Elevated serum matrix metalloproteinase-3 and -7 in H. pylori-related gastric cancer can be biomarkers correlating with a poor survival. Dig Dis Sci. 55:1649–1657. 2010. View Article : Google Scholar
30	Sugie S, Tsukino H, Mukai S, Akioka T, Shibata N, Nagano M and Kamoto T: Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese men. Tumour Biol. 35:2717–2721. 2014. View Article : Google Scholar
31	Lu J, Li XF, Kong LX, Ma L, Liao SH and Jiang CY: Expression and significance of cyclooxygenase-2 mRNA in benign and malignant ascites. World J Gastroenterol. 19:6883–6887. 2013. View Article : Google Scholar : PubMed/NCBI